Biosimilar timeline

TRULICITY biosimilars — when can they launch?

TRULICITY (DULAGLUTIDE) · BLA125469 · ELI LILLY AND CO

Reference exclusivity
2026-09-18
expired
Original approval
2014-09-18
FDA BLA125469
Originator
ELI LILLY AND CO
Marketed by Eli Lilly

Where TRULICITY sits in the biosimilar timeline

BPCIA reference product exclusivity for TRULICITY expired in 2026. Biosimilars are eligible for FDA 351(k) approval in the US. Active biosimilar applications and approvals will appear here as they're filed.

Under the US Biologics Price Competition and Innovation Act (BPCIA), a reference biologic is protected from biosimilar competition for 12 years from FDA approval (with 4 years of data exclusivity preventing 351(k) submissions). Biosimilars enter via the abbreviated 351(k) pathway, which requires comparability — not exact identity — to the reference product.

Key dates for TRULICITY

EventDateStatus
FDA approval (BLA filed by ELI LILLY AND CO) 2014-09-18 Past
4-year data exclusivity ends (first biosimilar 351(k) submission permitted) 2018-09-18 Past
12-year reference product exclusivity ends (first biosimilar can be marketed) 2026-09-18 Past

Note: composition-of-matter and method-of-use patent expiries (separate from BPCIA exclusivity) may set the actual launch window. See TRULICITY on Drug Landscape for the full patent picture.

Other ELI LILLY AND CO biologics

Sources

Not legal advice. BPCIA exclusivity may interact with composition-of-matter patents and patent term extensions — see the full drug profile for the consolidated picture.

Track TRULICITY biosimilar entry

Daily alerts when BPCIA exclusivity, ref-product patents, or biosimilar applications change. Free 3 watches, Pro 50.